However, the confirmatory phase III Keynote-122 clinical trial, which sought to evaluate the efficacy of pembrolizumab as compared to investigator’s choice chemotherapy in 253 patients with platinum-pretreated advanced NPC, failed to show any superiority of pembrolizumab over chemotherapy neither in the intention to treat population nor in the PD-L1 CPS ≥ 1 group (median OS 17.2 months vs. 15.3 months, p = 0.22) [12]. The gene discussed is CD274; the disease is nasopharyngeal carcinoma.